US FTC Finds Major Pharmacy Benefit Managers Inflated Drug Prices for $7.3 Billion Gain
UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts -- marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue in excess of the acquisition costs of the drugs,
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...
Hosted on MSN2d
What You Need To Know Ahead of CVS Health's Earnings ReleaseWith a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide ...
CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter ...
Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...
CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback